COURSE DIRECTORS

Arvin George, MD

Arvin George, MD is a Urologic Surgeon specializing in the diagnosis and management of genitourinary cancers. After obtaining his medical degree from the Royal College of Surgeons in Ireland, he completed his Urology Residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his Endourology fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a Urologic Oncology fellowship at the National Cancer Institute, National Institutes of Health. Dr. George’s clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. Dr. George’s research interests include minimally invasive and image-guided treatments, functional prostate imaging and focal therapy for prostate cancer.

Dr. George’s research focuses on the use of prostate MRI, MR/Ultrasound fusion-guided prostate biopsy, and focal therapy for prostate cancer. His research aims to identify appropriate use for imaging in diagnosis, risk stratification, and management of prostate cancer including active surveillance and selection/treatment of patients with novel focal therapy modalities.

Abhinav Sidana, MD

Abhinav Sidana, MD is an Assistant Professor of Clinical Surgery and the Director of Urologic Oncology and Focal Therapy program in the Division of Urology at University of Cincinnati Medical Center. His clinical practice includes both surgical and non-operative management of prostate, kidney, ureteral, testicular, and bladder cancers. Dr. Sidana is actively involved in urologic cancer research and his interests include functional prostate imaging, image-guided and focal treatments for prostate cancer and clinical trials on novel treatments for urologic cancers.

FACULTY

Andre Abreu, MD

Assistant Professor of Clinical Urology at the University of Southern California Institute of Urology, Los Angeles – CA, USA.

Co-director of Image-guided Surgery and Focal Therapy of Prostate Cancer at USC.

Expertise in minimally invasive and image-guided urologic surgery with focus on ablation therapy and robotic surgery, and image-fusion prostate biopsy. He has published several articles in reputed peer reviewed journals and (co)authored several book chapters.

Hashim Ahmed, MD

Professor Hashim Ahmed is currently Chair of Urology at Imperial College London. Hashim is an internationally renowned expert in prostate cancer diagnosis, imaging and biopsy as well as minimally invasive therapies for prostate cancer such as HIFU and cryotherapy – either whole-gland or focal therapy for primary prostate cancer or radiorecurrent disease. He has taught dozens of surgeons in these techniques in the UK and around the world and given numerous invited international lectures in this area. He has an extensive research portfolio with about £6M in grant income as a principal applicant and co-applicant to a research programme of approximately £14M. He has published over 150 peer-reviewed papers in areas that have led to key changes in the way we diagnose and treat men with localised prostate cancer. He currently holds a £2.1M Wellcome Trust Senior Clinical Research Fellowship and is Director of the Wellcome Trust Prostate Research in Imaging and Surgical Methodology (PRISM) Programme.

Mark Emberton, MD, FRCS

Mark Emberton is Professor of Interventional Oncology at UCL, an Honorary Consultant Urologist at University College Hospitals NHS Foundation Trust and Founding Pioneer of the charity Prostate Cancer UK.

Professor Emberton’s clinical research is aimed at improving the diagnostic and risk stratification tools and treatment strategies for prostate cancer (PCa); he specialises in the implementation of new imaging techniques, nanotechnologies, bio-engineering materials and non-invasive treatment approaches, such as high intensity focused ultrasound and photo-dynamic therapy.

Professor Emberton’s research has been published in >300 peer-reviewed scientific papers in journals including BMJ, Lancet Oncology and European Urology. He has also contributed to the development of guidelines for the management of PCa and lower-urinary tract symptoms, published by the International Society of Geriatric Oncology and the European Association of Urology.

Professor Emberton was appointed Dean of UCL Faculty of Medical Sciences in 2015. In addition he is a member of various urological and medical organisations (AAGUS, BAUS, EAU). He is a founding partner of London Urology Associates.

Inderbir Gill, MD

Dr. Inderbir Gill is chairman and Distinguished professor of the Catherine and Joseph Aresty Department of Urology, founding executive director of the USC Institute of Urology and associate dean for clinical innovation. Dr. Gill is an internationally recognized leader in the field of robotic and laparoscopic surgery for urologic cancers. An acclaimed innovator, he and his team are the world leaders in robotic urologic cancer surgery for prostate, kidney, and bladder cancer, having performed over 15,000 aggregate cases. For his outstanding work, Dr. Gill has received numerous prestigious awards, including the Dr. B.C. Roy National Award, presented by the President of India for Eminent Medical Person in India. It marked the first time a physician living outside of India was selected for this national award. Dr. Gill also was awarded the St. Paul’s Medal by the British Association of Urological Surgeons, which is the highest honor bestowed by the organization. He has published more than 750 peer-reviewed scientific papers, 50 book chapters and eight textbooks. He was elected to the prestigious American Association of Genito-Urinary Surgeons in 2003 and was selected as European Urology’s first North American editor. Dr. Gill is a distinguished researcher and prolific scholar. He has been listed among the Best Doctors in America for several years.

Amar Kishan, MD

Dr. Amar U. Kishan, Assistant Professor, is the Vice Chair of Clinical and Translational Research and Chief of the Genitourinary Oncology Service for the Department of Radiation Oncology at the David Geffen School of Medicine at UCLA and the UCLA Jonsson Comprehensive Cancer Center. Dr. Kishan graduated from the University of California, Berkeley with dual Bachelor of Arts degrees in Molecular and Cell Biology and Public Health. He earned his medical degree from Harvard Medical School, where he graduated magna cum laude from the joint Harvard-MIT Health Sciences and Technology Program. During medical school, he was awarded a Howard Hughes Medical Institute Fellowship to study tumor metabolism in the laboratory. He subsequently completed his internship training at Scripps Mercy Hospital in San Diego, where he was recognized as the H.H. Jones Intern of the Year. He then completed his residency training in radiation oncology at UCLA.

Dr. Kishan specializes in the utilization of radiation to treat genitourinary malignancies (particularly cancers of the prostate and bladder), as well as malignancies of the head and neck. He has an extensive research background and has published in leading journals such as JAMA, JAMA Oncology, European Urology, and Cancer Cell. He serves on several national committees and has received grant support from various national institutions, including the American Society of Radiation Oncology, the Radiological Society of North America, the Radiation Oncology Institute, and the Prostate Cancer Foundation.

Amir Lebastchi, MD

Dr. Lebastchi obtained his medical degree from the University of Hamburg in Germany. Following medical school at the University of Hamburg in Germany. Dr. Lebastchi completed then a postdoctoral fellowship in Vascular Biology and Immunology at Yale University before starting his surgical internship at Yale-New Haven Hospital. Dr. Lebastchi transitioned then to the University of Michigan where he completed his Urology training. He then joined the Urologic Oncology Branch at the National Cancer Institute (National Institutes of Health, NIH) where his clinical research interest focuses on optimization of prostate biopsy techniques, focal therapy and minimal invasive approaches in the treatment of prostate cancer.

Leonard S. Marks, MD

Leonard S. Marks, M.D., is a Professor of Urology at the David Geffen School of Medicine at UCLA. He graduated with honors (AOA) from the University of Texas, where he received both the M.D. and Masters of Arts (Physiology) degrees in 1969. He served an internship and residency in surgery at UCLA/Harbor General Hospital. He then served on active duty as Lt. Cdr. in the U.S. Public Health Service. He was later Research Fellow at Cedars/Sinai Medical Center and Post-Doctoral Research Scholar at UCLA School of Medicine. He completed his urology residency at UCLA and was Lecturer in Urology there in 1978, following which he entered private practice in Los Angeles. Dr. Marks was founder and medical director of Urological Sciences Research Foundation (USRF), a California non-profit organization (501c3), from its inception in 1992 through year-end 2008, when he joined the UCLA Department of Urology full-time. During that 17 year period, he led numerous studies on prostate diseases and men’s health and accumulated a publication list totaling more than 100 peer-reviewed articles.

He maintains membership in local, state, and national medical associations, as well as the American Urological Association, the American Association of Clinical Urologists, and other professional societies.

Peter Pinto, MD

Dr. Pinto is an Investigator and faculty member in the Urologic Oncology Branch of the National Cancer Institute, National Institutes of Health in Bethesda, Md. Following a residency in Urologic Surgery at Long Island Jewish Medical Center – Albert Einstein College of Medicine in New York, he was a Fellow and Clinical Instructor at the Brady Urologic Institute, Johns Hopkins Hospital. Dr. Pinto is a Board Certified Urologic Surgeon specializing in oncology and is the Director of the Urologic Oncology Fellowship Program at the National Cancer Institute. He is nationally and internationally recognized as an expert in the minimally invasive treatment of urologic cancers, specializing in laparoscopic and robotic surgery for prostate, kidney, bladder, and testicular cancer.

Thomas J. Polascik, MD

Thomas J. Polascik, M.D. is Professor of Surgery, Duke University Medical Center. He is Director of Surgical Technology, Duke Prostate and Urological Cancer Center. He is the founder and co-director, the International Symposium on Focal Therapy and Imaging of Prostate and Kidney Cancer that began at Duke in 2008. He currently is President of the Focal Therapy Society, Director of the Society of Urologic Oncology program and the Genitourinary Program on Focal Therapy at the Duke Cancer Institute. He is the Medical Director of Duke Men’s Health Initiative Screening event each September and is a governing member of several medical boards.

Art R. Rastinehad, DO

Art Rastinehad, D.O. joined the faculty at Mount Sinai as Associate Professor of Radiology and Urology. He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.

Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. Most recently, he is the principle investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques. Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health. This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate. As of May 2016, Dr Rastinehad was the first in the world to perform a gold nano-particle directed ablation using an transperineal MR US Fusion guided focal therapy system.

Stephen Scionti, MD

Dr. Stephen Scionti has had an interest in ablative prostate cancer treatments dating back to 2000 when he first began treating patients with cryotherapy. He has been offering HIFU to his patients since 2006. In 2009, he was appointed to the faculty at NYU and served as the Director of Prostate Cancer Ablative Surgery at NYU Langone Medical Center. In 2014, Dr. Scionti founded the Scionti Prostate Center in Sarasota, Florida and after FDA approval of HIFU technology in 2015, has been actively offering HIFU to his patients. As Medical Director for Vituro Health, Dr. Scionti has been actively involved in peer to peer physician training for the HIFU procedure and has been actively involved with HIFU outcomes research. Dr Scionti is one of the founding members of the Society of Ablative Urologic Surgeons (SAUS).

Samir Taneja, MD

Samir S. Taneja, MD is the James M. and Janet Riha Neissa Professor of Urologic Oncology, Professor of Urology and Radiology, and Director of the Division of Urologic Oncology at the NYU Langone Medical Center. He received his undergraduate and medical education at Northwestern University Medical School. He completed his surgical and urologic training at the University of California at Los Angeles and joined the NYU faculty in 1996. Dr Taneja is nationally renowned as a leader in the treatment and research of urologic cancers. His clinical practice has focused upon radical prostatectomy, partial nephrectomy, and complex tumor resection, by open and minimally invasive techniques. His laboratory research has focused in androgen receptor transcriptional activation and the relationship of AR to prostate cancer growth. He has previously overseen a research laboratory in androgen receptor biology, and has received funding through the National Insitutes of Health, Department of Defense, and the Prostate Cancer Foundation. In recent years, his clinical research interest has been in prostate cancer diagnostics, with particular focus on the use of imaging in the detection, risk stratification, and therapy of prostate cancer. He is internationally renowned as an expert in prostate cancer imaging, MRI-targeted prostate biopsy, and integration of MRI into clinical practice paradigms. He has lectured throughout the world on the use of prostate MRI in detection and therapy. He has served as Oncology Task Force Member and Chair, and Oncology Knowledge Assessment Test Co-Chair, for the American Board of Urology Exam Committee, Program Chair and Executive Committee Member for the Society of Urologic Oncology, and, most recently, Secretary General of the Urologic Research Society. He has authored over 150 articles, 25 book chapters, and 5 textbooks and periodicals on urologic cancer and urologic surgery. He is the Consulting Editor of the Urologic Clinics of North America and serves on the editorial board of European Urology. He is the previous Urology Surveys Upper Tract Oncology Editor, and the current Urology Surveys Prostate Cancer Editor for the Journal of Urology. He is editor of the 3rd, 4th, and upcoming 5th, editions of Taneja’s Complications of Urologic Surgery: Prevention and Diagnosis, one of the most widely read textbooks in American urology.

Sadhna Verma, MD

Sadhna Verma, MD

Srinivas Vourganti, MD

Srinivas Vourganti, MD, is an assistant professor in the Department of Urology. He is a robotic and minimally invasive urologic surgeon who specializes in the treatment of cancers of the prostate, bladder, kidney and ureter. As a urology fellow at the National Cancer Institute of the National Institutes of Health, Dr. Vourganti collaborated with world experts in clinical care, basic science and engineering to develop new ideas and bring them to the clinic. Dr. Vourganti is especially interested in refining translational imaging-based diagnostic and treatment methods as well as minimally invasive, image-targeted focal therapy of GU cancers.

Dr. Vourganti’s research has been widely published in leading peer-reviewed medical journals and he has authored numerous textbook chapters. He has been honored with numerous speaking invitations nationally and internationally. His expertise in the burgeoning field of imaging based prostate cancer diagnosis has been recognized and he has contributed as faculty in multiple hands-on courses in MR/US fusion guided prostate biopsy sponsored by the American Urological Association in order to contribute to the advancement of the greater Urologic community.

James Wysock, MD

I discovered my interest in medicine while I was an undergraduate studying chemical engineering, taking courses in the biological sciences. My interest grew and I ultimately decided to shift my career out of the laboratory and into the world of healthcare. My career in medicine combines my interest in the sciences and my desire to have a positive influence on the world around me.

My specialty is urologic oncology, which includes cancers of the kidneys, ureters, bladder, prostate, and testes. With the technology and advanced treatments available to me at NYU Langone, I am able to provide people with the most accurate diagnoses and highest level of care.

The field of urologic oncology often involves complex and sensitive decisions, and I believe that no single treatment is appropriate for all people. I aim to ensure that each person I treat is highly involved in making treatment decisions. Modern cancer care requires a team approach, and I routinely partner with my many excellent colleagues in oncology, radiology, pathology, and radiation oncology to offer the best care available for each patient.

I conduct research on advanced imaging techniques and treatment tools to optimize cancer diagnostics and therapy. Through thoughtful clinical trial design and execution, I hope to bring these novel options to patients. In addition to my clinical duties at NYU Langone, I also serve as the chief of the urology service at NYC Health + Hospitals/Bellevue.